Cortical ablation induces a spreading calcium-dependent, secondary pathogenesis which can be reduced by inhibiting calpain

Experimental Neurology

Volumn 155, Issue 2, 1999, Pages 315-326

  Bartus, Raymond T ^a,d   Chen, Er Yun ^b   Lynch, Gary ^c   Kordower, Jeffrey H ^b  

^a ALKERMES INC   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cal pain; Excitotoxicity; Inhibitors; Neurodegeneration; Neuroprotection; Neurosurgery; Proteolysis; Spectrin

Indexed keywords

CALPAIN; CALPASTATIN; GLUTAMIC ACID; SPECTRIN;

ARTICLE; BRAIN CORTEX; BRAIN INJURY; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; LATERAL GENICULATE NUCLEUS; MALE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINASE INHIBITION; RAT; TOPICAL DRUG ADMINISTRATION; VISUAL SYSTEM;

EID: 0032980358     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.7001     Document Type: Article

References (29)

1. Neuroprotection in CNS Diseases. 1997;Dekker, New York.
2. Bartus R. T., Tracy M. A., Emerich D. F., Zale S. E. Sustained delivery of proteins for novel therapeutic products. Science. 281:1998;1161-1162.
3. Bartus R. T. The calpain hypothesis of neurodegeneration: Evidence for a common cytotoxic pathway. Neuroscientist. 3:1997;314-327.
4. Bartus R. T., Hayward N. J., Elliott P. J. Calpain inhibitor AK295 protects neurons from focal brain ischemia: Effects of postocclusion intra-arterial administration. Stroke. 25:1994;2265-2270.
5. Bartus R. T., Hayward N. J., Elliott P. J., Sawyer S. D., Baker K. L., Reginald L. D., Akiyama A., Straub J. A. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J. Cereb. Blood Flow Metab. 14:1994;2265-2270.
6. Bartus R. T., Dean R. L., Cavanaugh K., Ereleth D., Carreiro D., Lynch G. Time-related neuronal changes following middle cerebral artery occlusion: Implications for therapeutic intervention and the role of calpain. J. Cereb. Blood Flow Metab. 15:1995;969-979.
7. Bartus R. T., Elliott P. J., Hayward N. J., Dean R. L., Harbeson S., Straub J. A., Li Z., Powers J. C. Calpain as a novel target for treating acute neurodegenerative disorders. Neurol. Res. 17:1995;249-258.
8. Bartus R. T., Dean R. L., Mennerick S., Eveleth D., Lynch G. Temporal ordering of pathogenic events following transient global ischemia. Brain Res. 790:1998;1-13.
9. Black P. M. Brain tumors. N. Engl. J. Med. 324:1991;1471-1476.
10. Brem H., Piantadosi S., Burger P. C., Walker M., Selker R., Vick N. A., Black K., Sisti M., Brem S., Mohr G., Muller P., Morawetz R., Schold S. C. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 345:1995;1008-1112.
11. Choi D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
12. Cummings B. J., Cotman C. W. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 346:1995;1524-1528.
13. Harbaugh R. E. Novel CNS-directed drug delivery systems in Alzheimer's disease and other neurological disorders. Neurobiol. Aging. 10:1989;623-629.
14. Hong S.-C., Goto Y., Lanzino G., Soleau B. A., Kassell N. F., Lee K. S. Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. Stroke. 25:1994;663-669.
15. Hong S.-C., Lanzino G., Goto Y., Kang S. K., Schottler F., Kassell N. F., Lee K. S. Calcium-activated proteolysis in rat neocortex induced by transient focal ischemia. Brain Res. 661:1994;43-50.
16. Ivy G. O., Seubert P., Baudry M., Lynch G. Presence of brain specctrin in dendrites of mammalian brain: Technical factors involved in immunocytochemical detection. Synapse. 2:1988;329-333.
17. Johnson O. L., Cleland J. L., Lee H. J., Charnis M., Duenas E., Jaworowicz W., Shepard D., Shahzamani A., Jones A. J. S., Putney S. D. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med. 2:1996;795-799.
18. Lee K. S., Frank S., Vanderklish P., Arai A., Lynch G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc. Natl. Acad. Sci. USA. 88:1991;7233-7237.
19. Meldrum B. Excitatory amino acid transmission. Neurol. Neurobiol. 24:1987;189-196.
20. Melloni E., Pontremoli S. The calpains. Trends Neurosci. 12:1989;438-444.
21. Roberts-Lewis J. M., Savage M. J., Marcy V. R., Pisker L. R., Siman R. Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J. Neurosci. 14:1994;3934-3944.
22. Saatman K. E., Bozyczko-Coyne D., Marcy V., Siman R., McIntosh T. K. Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J. Neuropathol. Exp. Neurol. 55:1996;850-860.
23. Saatman K. E., Murai H., Bartus R. T., Hayward N. J., Perri B. R., McIntosh T. K. The calpain inhibitor, AK295, attenuates sensory/motor and cognitive deficits following experimental brain injury in the rat. Proc. Natl. Acad. Sci. USA. 93:1996;3428-3433.
24. Saido T. C., Yokota M., Nagao S., Yamaura I., Tani E., Tsuchiya T., Suzuki K., Kawashima S. Spatial resolution of fodrin proteolysis in postischemic brain. J. Biol. Chem. 268:1993;25239-25243.
25. Seubert P., Lee K., Lynch G. Ischemia triggers NMDA receptor-linked cytoskeletal proteolysis in hippocampus. Brain Res. 492:1989;366-370.
26. Siman R., Noszek J. C., Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J. Neurosci. 9:1989;1579-1590.
27. Siman R., Baudry M., Lynch G. Brain fodrin: Substrate for calpain I, an endogenous calcium-activated protease. Proc. Natl. Acad. Sci. USA. 81:1984;3572-3576.
28. Takahashi K. Calpain substrate specificity. Mellgren R. L., Murachi T. Intracellular Calcium Dependent Proteolysis. 1990;55-74 CRC Press, Boca Raton.
29. Yao H., Ginsberg M. D., Eveleth D. D., LaManna J. C., Wastson B. D., Alonso J. F., Loor J. Y., Foreman J. H., Burto R. Local cerebral glucose utilization and cytoskeletal proteolysis as indices of evolving focal ischemic injury in core and penumbra. J. Cereb. Blood Flow Metab. 15:1995;398-408.